• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

TYRX Inc.

Move carefully to the exit, veteran medtech sellers warn

June 6, 2018 By Nancy Crotti

Beyond their altruistic and sales goals, medical device startups generally keep an eye out for the exit. Getting there requires planning, patience and persistence, according to a couple of medtech executives who’ve been through it. Martha Shadan headed Plymouth, Minn.–based Rotation Medical, a private company sold to Smith & Nephew in December 2017, just three […]

Filed Under: Business/Financial News, DeviceTalks Q&A, Mergers & Acquisitions Tagged With: DeviceTalks Minnesota, devicetalksminnesota, Entellus Medical Inc., Medtronic, rotationmedical, Smith & Nephew, startups, Stryker, TYRX Inc.

FDA warns Medtronic’s Tyrx on anti-bacterial envelopes

June 22, 2016 By Brad Perriello

The FDA sent a warning letter earlier this month to Medtronic (NYSE:MDT) subsidiary Tyrx over problems with its process validation and quality systems. The Tyrx envelopes are designed to elute a pair of anti-microbial drugs, minocycline and rifampin, for 7 days before dissolving over a period of roughly 9 weeks. They’re cleared for use with pacemakers, implantable cardioverter-defibrillators, cardiac […]

Filed Under: Regulatory/Compliance, Surgical Tagged With: Medtronic, TYRX Inc., Warning Letter

FDA clears Medtronic’s Tyrx envelope for DBS devices

October 8, 2015 By Brad Perriello

Medtronic (NYSE:MDT) said today that it’s launching its Tyrx surgical envelope in the U.S. for use with deep-brain stimulation devices, after it won 510(k) clearance from the FDA for use of the infection-fighting envelope with implantable neurostimulators. Fridley, Minn.-based Medtronic said it’s planning to make the Tyrx device, acquired for $160 million in January 2014, available for […]

Filed Under: Cardiovascular, Food & Drug Administration (FDA), Neuromodulation/Neurostimulation, Regulatory/Compliance, Surgical Tagged With: Medtronic, TYRX Inc.

Medtronic launches trial for Tyrx implant envelope

January 7, 2015 By Brad Perriello Leave a Comment

Medtronic launches trial for Tyrx implant envelope

Medtronic (NYSE:MDT) said today that it’s launching a new clinical trial to evaluate the anti-bacterial cardiac implant envelope it bought along with Tyrx for $160 million last year.

Filed Under: News Well Tagged With: Cardiac Rhythm Management, Clinical Trials, TYRX Inc.

BSX wins CE Mark approval for Vercise deep-brain stim device | Regulatory news for the week of September 22, 2014

September 23, 2014 By MassDevice Leave a Comment

Boston Scientific wins CE Mark for Vercise brain stim device

September 17, 2014 by Brad Perriello

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: Boston Scientific, TYRX Inc., VertiFlex Inc.

Medtronic wins CE Mark for Tyrx cardiac device envelope

September 22, 2014 By Brad Perriello Leave a Comment

Medtronic wins CE Mark for Tyrx heart envelope

Filed Under: News Well, Regulatory/Compliance Tagged With: Cardiac Rhythm Management, CE Mark, TYRX Inc.

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

September 3, 2014 By Brad Perriello Leave a Comment

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

Bluegrass Vascular Technologies said it named Gabriele Niederauer its new president & CEO, hard on the heels of a Series A funding round that brought in $4.5 million for its Surfacer central venous catheter.

Filed Under: News Well Tagged With: ArthroCare Corp., Biolase, Bluegrass Vascular Technologies, Bovie Medical Corp., Copan Group, European Society of Cardiology, Evaluate Ltd., LED Medical Diagnostics Inc., Medina Medical, Novadaq, Personnel Moves, Philips, Smith & Nephew, TYRX Inc.

Medtronic acquires drug/device maker TYRX for $160M

January 6, 2014 By Arezu Sarvestani Leave a Comment

Medtronic nabs drug/device maker TYRX for $160M

Minnesota medical device giant Medtronic (NYSE:MDT) announced today that it acquired privately owned TYRX, maker of surgical infection prevention products.

Filed Under: Drug-Device Combinations, Mergers & Acquisitions, News Well, Surgical Tagged With: Minnesota, Patient Safety, TYRX Inc.

TYRX wins 510(k) clearance for anti-bacterial envelope

December 9, 2013 By Chris Walker Leave a Comment

TYRX wins 510(k) clearance for anti-bacterial envelope

TYRX won 510(k) clearance from the FDA to expand marketing indications for its AIGISRx N antibacterial envelope to include use with spinal cord neuromodulators.

The Monmouth Junction, N.J.-based company may now market the device as a tool to help reduce surgical site infections associated with implantable devices for both neurology and cardiology.

Filed Under: Food & Drug Administration (FDA), Hospital Care, News Well, Surgical Tagged With: Patient Safety, TYRX Inc.

TYRX lands FDA win for antibacterial surgical envelope

July 12, 2013 By Sony Salzman Leave a Comment

TYRX, Inc. wins 510(k) for its antibacterial surgical envelope

The FDA granted 510(k) to New Jersey-based TYRX for its next-generation AIGISRx R Antibacterial Envelope, indicated to address high infection rates after pacemaker and implantable cardioverter defibrillator implantation surgeries.

Filed Under: Cardiac Implants, Hospital Care, News Well, Regulatory/Compliance, Surgical Tagged With: TYRX Inc.

Second Sight eyes $25M funding round | Wall Street Beat

January 29, 2013 By MassDevice staff Leave a Comment

MassDevice.com Wall Street Beat

Second Sight Medical registered with the SEC for a $25 million offering of equity, debt, options and warrants as it waits for the FDA to decide whether to give the green light to its "bionic eye" retinal implant.

The Sylmar, Calif.-based medical device company filed with the securities watchdog agency yesterday, saying it has yet to sell any of the $1,000 shares in the offering.

Filed Under: Funding Roundup, News Well, Optical/Ophthalmic, Wall Street Beat Tagged With: Bausch + Lomb, Baxter, GE Healthcare, second-sight-medical, TYRX Inc., Zytoprotec

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS